News | March 01, 2025
Biocon launches GLP -1, Liraglutide, in UK
The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.
The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.
Standalone profit from operations for Q4-2024 were Rs. 108 crore
Biocon Foundation has been steadfast in its mission to empower underserved communities through innovative healthcare solutions, education, and sustainable development initiatives
We have big plans across our B2C and B2B businesses in India and abroad
USFDA inspection at Emcure Pharmaceuticals API facility
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
This launch of Epinephrine Injection multiple-dose Vial is eligible for 180 days of CGT exclusivity under section 505(j)(5)(B)(v) of the FD&C Act.
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
Subscribe To Our Newsletter & Stay Updated
